Overview: CJC-1295 with DAC evidence guide: human GH and IGF-1 studies, with-DAC versus no-DAC terminology, Australian regulation and 2026 WADA status.
On this page
Last reviewed: 28 September 2026. CJC-1295 with DAC is an experimental, long-acting analogue of growth-hormone-releasing hormone (GHRH). The drug-affinity-complex design allows the molecule to bind circulating albumin, extending exposure far beyond native GHRH. Human studies show sustained changes in growth hormone (GH) and insulin-like growth factor 1 (IGF-1), but they do not establish anti-ageing, recovery, body-composition or performance benefits.
CJC-1295 with DAC at a glance
| Drug class | Long-acting GHRH analogue |
|---|---|
| DAC meaning | Drug affinity complex; designed for covalent binding to endogenous albumin |
| Human evidence | Small, early pharmacokinetic and pharmacodynamic studies in healthy adults |
| What was measured | Drug persistence, GH secretion patterns and IGF-1 concentrations |
| What remains unproven | Clinical benefits for ageing, sleep, recovery, fat loss, muscle gain or disease treatment |
| Australian context | The TGA has specifically identified CJC-1295 among unapproved peptide products of public-health concern |
What is CJC-1295 with DAC?
CJC-1295 is a modified version of the first 29 amino acids of human GHRH. Native GHRH is cleared quickly. CJC-1295 was engineered to resist enzymatic breakdown, while the DAC component reacts with a free thiol group on albumin. Albumin binding produces much longer systemic exposure than the unmodified hormone fragment.
The foundational pharmacology paper described CJC-1295 as a stable, active hGRF(1-29) analogue with an extended plasma half-life. This mechanism explains why evidence from the DAC version cannot simply be transferred to short-acting analogues.
Jetté et al.: identification and pharmacology of CJC-1295 (PMID 15817669)
What did the early human studies show?
Sustained GH and IGF-1 changes
A 2006 study reported results from two randomised, placebo-controlled trials in healthy adults. CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1. The estimated half-life was 5.8 to 8.1 days. The study was designed to characterise pharmacokinetics, endocrine responses and short-term tolerability—not to test clinical outcomes such as body composition, physical recovery, sleep quality or longevity.
Teichman et al.: prolonged GH and IGF-1 stimulation in healthy adults (PMID 16352683)
GH pulsatility study
A second 2006 study used frequent overnight blood sampling in healthy men before and one week after administration. GH secretion remained pulsatile, while trough and mean GH secretion and IGF-1 increased. This helps describe endocrine physiology under prolonged stimulation, but it remains a small mechanistic study rather than evidence of a health or performance benefit.
Ionescu and Frohman: GH pulsatility during CJC-1295 exposure (PMID 17018654)
With DAC versus “no DAC”
Online labels create avoidable confusion. “CJC-1295 with DAC” refers to the long-acting albumin-binding molecule evaluated in the best-known human studies. “CJC-1295 no DAC” is commonly used as a marketing name for shorter-acting modified GRF(1-29). That does not make the products equivalent.
| Feature | CJC-1295 with DAC | “No DAC” / modified GRF(1-29) |
|---|---|---|
| Albumin-binding DAC group | Present | Absent |
| Exposure profile | Long acting; measured in days in early studies | Much shorter acting |
| Published human evidence | Early pharmacokinetic and endocrine studies | Cannot borrow the DAC study results |
| Interpretation | Persistent GH-axis stimulation | Different molecule and exposure pattern |
Names alone are not sufficient for identity. A research report should state the exact molecular form and use suitable identity testing. See the site’s laboratory-testing methodology guide.
What the evidence does not prove
An increase in a biomarker is not the same as a demonstrated clinical benefit. The early studies do not establish that CJC-1295:
- improves muscle mass, fat loss or athletic performance;
- accelerates recovery from injury or training;
- improves sleep quality or cognition;
- slows ageing or extends lifespan;
- treats growth-hormone deficiency or another disease; or
- is safe for long-term, repeated or unsupervised use.
These questions would require appropriately designed clinical trials with meaningful outcomes, adequate follow-up and a clearly characterised product.
Safety and evidence gaps
The available human evidence is small and short term. Prolonged stimulation of the GH/IGF-1 axis raises questions that early pharmacology studies cannot resolve, including glucose regulation, fluid retention, cardiovascular effects, tissue growth, long-term endocrine feedback and immunogenicity. Product-level risks also include incorrect identity, concentration, contamination, sterility failure and endotoxin—none of which can be ruled out by a single HPLC area-percentage result.
Our HPLC chromatogram guide explains why chromatographic peak area is not the same as complete identity, assay, sterility or safety evidence.
CJC-1295 in Australia
In June 2026, the Therapeutic Goods Administration and Australia’s Chief Medical Officer warned about unapproved peptide products and specifically named CJC-1295. The TGA states that unapproved products not included in the Australian Register of Therapeutic Goods have not been evaluated for safety, quality or effectiveness. It also highlights manufacturing, labelling, contamination, sterility and dosing uncertainty.
A “research use only” statement does not override therapeutic-goods law when a product is promoted or supplied for therapeutic use. Current status should be checked in the ARTG and against TGA guidance. See our Australian peptide regulation guide.
TGA and Chief Medical Officer: concerns regarding unapproved peptide products (19 June 2026)
Sport and anti-doping status
The World Anti-Doping Agency’s 2026 Prohibited List includes CJC-1295 under growth-hormone releasing factors. It is prohibited at all times, in and out of competition. Athletes should use official anti-doping resources and seek qualified advice rather than relying on product marketing.
Frequently asked questions
What does DAC mean in CJC-1295?
DAC means drug affinity complex. It was designed to bind the peptide to endogenous albumin and extend its persistence in circulation.
Is CJC-1295 with DAC the same as CJC-1295 no DAC?
No. The commonly marketed “no DAC” form is a shorter-acting modified GHRH fragment. The molecular form, exposure profile and applicable evidence are different.
Do the human trials prove fat loss, muscle gain or anti-ageing effects?
No. The principal human studies measured pharmacokinetics and endocrine markers such as GH and IGF-1. They were not outcome trials for fat loss, muscle gain, recovery, sleep or longevity.
Is CJC-1295 approved in Australia?
Approval is product- and indication-specific. The TGA has named CJC-1295 among unapproved peptide products of concern. Verify any product through the ARTG and current TGA guidance.
Does Elite Peps Australia sell CJC-1295?
No. This is an independent educational profile. The site does not sell, recommend or provide instructions for using CJC-1295.
Related reading
- CJC-1295 and ipamorelin: evidence, safety and WADA status
- Australian peptide regulation and ARTG checks
- How to read an HPLC chromatogram
Primary and regulatory sources
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates. 2005. PMID 15817669.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. 2006. PMID 16352683.
- Ionescu M, Frohman LA. Pulsatile GH secretion persists during continuous stimulation by CJC-1295. 2006. PMID 17018654.
- Therapeutic Goods Administration and Chief Medical Officer statement. 19 June 2026.
- World Anti-Doping Agency 2026 Prohibited List.
Editorial note: Educational scientific information only. This page does not provide medical advice, dosing guidance, preparation instructions or purchasing information.
How to cite this research profile
CJC-1295 with DAC: Human Evidence & Australia (2026). Elite Peps Australia. Published 30 June 2026; updated 28 September 2026. https://elitepepsaustralia.com/product/cjc-1295-dac/
Verification: Follow the linked primary studies, trial records and regulator documents in the references above. Regulatory status is date-sensitive.